← Back to all articles
PharmacologyPubMed Verified

Neuroprotective potential of ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease

Katchborian-Neto A, Santos MFC, Nicacio KJ, Correa JOA, Murgu M, Martins TMM, Gomes DA, Goes AM, Soares MG, Dias DF, Chagas-Paula DA

Journal of Ethnopharmacology (2020)

Preclinical in vitro
Abstract

Evaluated neuroprotective potential of ayahuasca and its plant components in a Parkinson's disease cell model using 6-OHDA-induced neurodegeneration. Crude extracts and alkaloid fractions showed neuroprotective effects. Untargeted metabolomics identified beta-carbolines and monoterpene indole alkaloids as key neuroprotective compounds.

Citations75
Study TypePreclinical in vitro
Parkinson's diseaseneuroprotectionmetabolomics6-OHDAbeta-carbolines
DOI: 10.1016/j.jep.2020.112743View on PubMed

Related Articles

Pharmacology

Psychoactive substances of natural origin: toxicological aspects, therapeutic properties and analysis in biological samples

Goncalves J, Luis A et al.

Molecules, 2021
Pharmacology

Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca

McKenna DJ, Towers GHN et al.

Journal of Ethnopharmacology, 1984
Pharmacology

Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells

Salles G, de Carvalho Alves I et al.

Archives of Toxicology, 2025
Pharmacology

Ayahuasca pretreatment prevents sepsis-induced anxiety-like behavior, neuroinflammation, and oxidative stress, and increases brain-derived neurotrophic factor

da Silva FS, Silva EAS et al.

Journal of Psychiatric Research, 2023